Altimmune (ALT) Deferred Taxes (2012 - 2025)

Altimmune (ALT) posted quarterly Deferred Taxes of -$681000.0 for Q1 2025, up 92.6% quarter-over-quarter from -$9.2 million in Q4 2018.

Altimmune (ALT) Deferred Taxes (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Deferred Taxes for 8 consecutive years, with -$681000.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Deferred Taxes changed N/A year-over-year to -$681000.0; the TTM figure through Dec 2025 stood at -$681000.0 (changed N/A YoY), while the FY2025 annual figure was -$681000.0, changed N/A from the prior year.
Deferred Taxes rose to -$681000.0 in Q1 2025 per ALT's latest filing, from -$9.2 million in the prior quarter.
Across five years, Deferred Taxes topped out at -$681000.0 in Q1 2025 and bottomed at -$681000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Altimmune	571.75 Mn	571.75 Mn	-	-

Download Data